10-Q: Nortech Systems Reports Q2 Profit Amidst YTD Loss

Nortech Systems Inc. reported a net income for Q2 2025, but a significant net loss for the first half of the year, alongside ongoing financial covenant challenges and strategic operational adjustments.

Summary

• Net sales for the three months ended June 30, 2025, decreased by 9.5% to $30,675 thousand compared to $33,891 thousand in the prior year.
• Gross profit for Q2 2025 increased by 4.8% to $4,837 thousand, with gross margin improving to 15.8% from 13.6% in Q2 2024.
• Operating income for Q2 2025 rose significantly by 115.7% to $742 thousand from $344 thousand in Q2 2024.
• Net income for Q2 2025 was $313 thousand, up from $157 thousand in Q2 2024.
• For the six months ended June 30, 2025, net sales decreased by 15.5% to $57,570 thousand from $68,106 thousand in the prior year.
• The company reported an operating loss of $(871) thousand and a net loss of $(1,003) thousand for the first six months of 2025, compared to operating income of $1,499 thousand and net income of $922 thousand in the same period of 2024.
• Cash used in operating activities increased to $(2,773) thousand for the six months ended June 30, 2025, from $(1,458) thousand in the prior year period.
• Total order backlog as of June 30, 2025, increased by 6.9% to $78,351 thousand compared to the prior year, primarily driven by large medical device orders.
• The company completed the sale of its Blue Earth manufacturing facility in July 2025 for $500 thousand.
• Nortech Systems amended its Senior Secured Revolving Line of Credit multiple times to waive non-compliance with financial covenants and extend the expiration date to August 31, 2026.

Sentiment

Score: 4

Explanation: While Q2 showed some operational improvements and a positive net income, the year-to-date performance reflects a significant net loss and increased cash burn from operations. The ongoing need for waivers on financial covenants and increased borrowing rates indicate underlying financial challenges, despite management's stated confidence in liquidity. The increase in total backlog is a positive, but overall, the financial position remains precarious.

Positives

• Gross profit margin improved to 15.8% in Q2 2025 from 13.6% in Q2 2024, indicating better plant utilization and favorable sales mix.
• Operating income for Q2 2025 increased by 115.7% to $742 thousand, demonstrating improved operational efficiency in the quarter.
• Net income for Q2 2025 nearly doubled to $313 thousand from $157 thousand in Q2 2024.
• Total order backlog increased by 6.9% to $78,351 thousand as of June 30, 2025, driven by large medical device orders, suggesting future revenue potential.
• The sale of the Blue Earth facility for $500 thousand in July 2025 provides additional cash and completes a restructuring initiative.
• Received waivers for non-compliance with financial covenants and successfully extended the Revolver expiration, maintaining access to credit.

Negatives

• Net sales decreased by 9.5% in Q2 2025 and 15.5% for the six months ended June 30, 2025, compared to the prior year periods.
• The company reported a significant operating loss of $(871) thousand and a net loss of $(1,003) thousand for the first six months of 2025, a substantial decline from prior year profitability.
• Cash used in operating activities increased to $(2,773) thousand for the six months ended June 30, 2025, indicating higher cash burn from operations.
• Medical Device sales decreased by 21.5% and Aerospace and Defense sales decreased by 32.2% for the six months ended June 30, 2025.
• The company was not in compliance with leverage ratio and minimum fixed charge ratio covenants, requiring multiple amendments and waivers to its credit agreement.
• Borrowing rates on the line of credit increased by a total of 125 basis points due to amendments related to covenant non-compliance.

Risks

• Failure to comply with financial covenants in the credit agreement could lead to accelerated repayment obligations and inability to secure additional financing.
• Potential impairment of long-lived assets if fair value declines below carrying value, which could negatively impact financial results and debt covenants.
• Volatility in the marketplace affecting market supply, demand of products, or currency exchange rates.
• Supply chain disruption and unreliability, and lack of sufficient human resources to produce products.
• Increased competition within the EMS industry or decisions by OEMs to cease or limit outsourcing.
• Changes in the reliability and efficiency of operating facilities or those of third parties.
• Increases in raw material costs (e.g., copper, oil) and commodity/energy cost instability.
• Risks related to FDA noncompliance for medical products.
• Loss of a major customer could significantly impact revenue and profitability.
• General economic, financial, and business conditions could adversely affect financial condition and results of operations.
• Increased or unanticipated costs related to compliance with securities and environmental regulation.
• Disruption of global or local information management systems due to natural disaster or cyber-security incidents.
• Outbreaks of epidemic, pandemic, or contagious diseases affecting operations, customers, or suppliers.
• No assurance that Marpe Technologies medical device operations will be commercially successful or raise additional funds, impacting the value of services provided by the company.

Future Outlook

The company believes its existing financing arrangements, anticipated cash flows from operations, and cash on hand will be sufficient to satisfy working capital needs, capital expenditures, and debt repayments for the next twelve months. Management expects delays in Aerospace and Defense customer approvals and manufacturing/plant utilization inefficiencies to be resolved over the next two quarters. Plant optimization activities, cost-cutting initiatives, and planned inventory reductions are intended to drive reduced borrowings during the remainder of 2025.

Management Comments

• We believe that our existing financing arrangements, anticipated cash flows from operations and cash on hand will be sufficient to satisfy our working capital needs, capital expenditures and debt repayments for the next twelve months.
• We expect these matters [delays in Aerospace and Defense customer approvals of products transferred from our Blue Earth facility to our Bemidji facility as well as manufacturing and plant utilization inefficiencies related to the movement of various production between plants] to be resolved over the next two quarters.
• We have implemented plant optimization activities and cost cutting initiatives in the first two quarters of 2025 to address losses.
• These actions plus continued efforts to improve manufacturing efficiencies in the remainder of 2025 and the planned reduction in inventory levels are intended to drive reduced borrowings during the remainder of 2025.

Industry Context

Nortech Systems operates as a full-service global EMS contract manufacturer, serving the Medical Device, Medical Imaging, Aerospace and Defense, and Industrial markets. The company's focus on complex electromedical and electromechanical products positions it in a specialized segment of the EMS industry. The reported decline in sales, particularly in Medical Device and Aerospace and Defense, suggests specific customer or internal challenges rather than broad industry downturns, especially given the growth in Medical Imaging. The strategic investments in global footprint expansion and lean manufacturing initiatives align with broader industry trends towards efficiency and specialized capabilities.

Corporate Governance

Related Party Transactions

• David Kunin, Chairman, was a minority owner of Abilitech Medical, Inc. The company wrote off remaining accounts receivable from Abilitech in 2024 as Abilitech ceased operations.
• David Kunin, Chairman, is a minority owner (<10%) and Board member of Marpe Technologies, LTD, an early-stage medical device company.
• The company and Marpe Technologies received approval for a $1,000 thousand conditional grant from the Israel-United States Binational Industrial Research and Development Foundation (BIRD Foundation), with each receiving $500 thousand.
• The company met its $500 thousand contribution obligation by providing services at cost or no cost to Marpe Technologies.
• The company will receive a 10-year exclusive right to manufacture Marpe Technologies products, contingent on Marpe's commercial success and ability to raise additional funds.

Stakeholder Impact

• Shareholders: Experienced a net loss for the first half of 2025, but Q2 showed improved profitability. The ongoing covenant issues and increased borrowing costs could impact future profitability and share value. The increase in total backlog and sale of the Blue Earth facility offer some positive long-term prospects.
• Employees: Restructuring charges included severance for staff reductions in Q1 2025, indicating workforce adjustments.
• Customers: Delays in Aerospace and Defense customer approvals and manufacturing inefficiencies impacted product delivery and customer satisfaction.
• Creditors (Bank of America): The company's non-compliance with financial covenants required waivers and amendments, leading to increased borrowing rates and stricter monitoring, reflecting higher credit risk.

Next Steps

• Resolve delays in Aerospace and Defense customer approvals and manufacturing/plant utilization inefficiencies over the next two quarters.
• Continue plant optimization activities and cost-cutting initiatives to address losses.
• Implement planned reduction in inventory levels to drive reduced borrowings during the remainder of 2025.
• Maintain compliance with amended financial covenants (leverage ratio of 2.5x and fixed charge coverage ratio of 1.25x) by Q4 2025 and thereafter.
• Maintain adjusted EBITDA of at least $1,300 thousand for Q3 2025 and at least $1,600 thousand for Q4 2025 and each quarter thereafter.
• Maintain Liquidity (unrestricted cash and Revolver availability) of at least $2,500 thousand.

Key Dates

Recommendation

While the company showed a positive net income and improved gross margin in Q2 2025, the significant net loss for the first half of the year and persistent non-compliance with credit facility covenants are major concerns. The successful negotiation of waivers and extension of the credit line provides short-term stability, but the increased borrowing costs and ongoing operational inefficiencies (e.g., A&D customer approval delays) suggest continued headwinds. The growth in total backlog, particularly in medical devices, is a positive indicator for future revenue, but execution risks remain high. A 'hold' recommendation is appropriate given the mixed signals: some operational improvements and backlog growth are offset by a challenging financial performance year-to-date and ongoing liquidity management issues.

Keywords

Contract Manufacturing, EMS, Medical Device, Medical Imaging, Aerospace and Defense, Industrial, SEC Filing, 10-Q, Financial Results, Revenue, Profit, Backlog, Restructuring, Credit Agreement, Covenant Waiver, Liquidity